EP3113771A4 - Therapeutic uses of ibogaine and related compounds - Google Patents

Therapeutic uses of ibogaine and related compounds Download PDF

Info

Publication number
EP3113771A4
EP3113771A4 EP15758129.9A EP15758129A EP3113771A4 EP 3113771 A4 EP3113771 A4 EP 3113771A4 EP 15758129 A EP15758129 A EP 15758129A EP 3113771 A4 EP3113771 A4 EP 3113771A4
Authority
EP
European Patent Office
Prior art keywords
ibogaine
related compounds
therapeutic uses
therapeutic
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15758129.9A
Other languages
German (de)
French (fr)
Other versions
EP3113771A1 (en
Inventor
Emeline Maillet
Lawrence Friedhoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DemeRx Inc
Original Assignee
DemeRx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DemeRx Inc filed Critical DemeRx Inc
Publication of EP3113771A1 publication Critical patent/EP3113771A1/en
Publication of EP3113771A4 publication Critical patent/EP3113771A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
EP15758129.9A 2014-03-03 2015-03-02 Therapeutic uses of ibogaine and related compounds Withdrawn EP3113771A4 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201461947397P 2014-03-03 2014-03-03
US201461952724P 2014-03-13 2014-03-13
US201461952743P 2014-03-13 2014-03-13
US201461952718P 2014-03-13 2014-03-13
US201461952740P 2014-03-13 2014-03-13
US201461952736P 2014-03-13 2014-03-13
US201461952725P 2014-03-13 2014-03-13
US201462049968P 2014-09-12 2014-09-12
PCT/US2015/018356 WO2015134405A1 (en) 2014-03-03 2015-03-02 Therapeutic uses of ibogaine and related compounds

Publications (2)

Publication Number Publication Date
EP3113771A1 EP3113771A1 (en) 2017-01-11
EP3113771A4 true EP3113771A4 (en) 2017-10-25

Family

ID=54055765

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15758129.9A Withdrawn EP3113771A4 (en) 2014-03-03 2015-03-02 Therapeutic uses of ibogaine and related compounds

Country Status (4)

Country Link
EP (1) EP3113771A4 (en)
AU (2) AU2015225442A1 (en)
CA (2) CA3212001A1 (en)
WO (1) WO2015134405A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9561233B2 (en) 2014-03-13 2017-02-07 Demerx, Inc. Use of ibogaine for the treatment of pain
US9592239B2 (en) 2014-09-12 2017-03-14 Demerx, Inc. Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US20230023092A1 (en) 2019-04-17 2023-01-26 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin
KR20220074908A (en) * 2019-10-01 2022-06-03 마인드 메디슨, 인크. 18-MC for the treatment of substance use disorders
JP2023520844A (en) * 2020-04-16 2023-05-22 パイク セラピューティクス，インコーポレイテッド Transdermal microdosing delivery of hallucinogen derivatives
US20220409628A1 (en) * 2021-06-29 2022-12-29 Mind Medicine, Inc. 18-mc for treating obesity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857523A (en) * 1988-07-18 1989-08-15 Nda International, Inc. Rapid method for attenuating the alcohol dependency syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629307A (en) * 1989-10-20 1997-05-13 Olney; John W. Use of ibogaine in reducing excitotoxic brain damage
EP2083825A4 (en) * 2006-09-26 2009-11-04 Addiction Res Inst Inc Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857523A (en) * 1988-07-18 1989-08-15 Nda International, Inc. Rapid method for attenuating the alcohol dependency syndrome

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AMIR H. REZVANI ET AL: "Attenuation of alcohol intake by Ibogaine in three strains of alcohol-preferring rats", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR., vol. 52, no. 3, 1 November 1995 (1995-11-01), US, pages 615 - 620, XP055223408, ISSN: 0091-3057, DOI: 10.1016/0091-3057(95)00152-M *
DEBORAH C. MASH ET AL: "Ibogaine: Complex Pharmacokinetics, Concerns for Safety, and Preliminary Efficacy Measures", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 914, no. 1, 1 September 2000 (2000-09-01), US, pages 394 - 401, XP055407277, ISSN: 0077-8923, DOI: 10.1111/j.1749-6632.2000.tb05213.x *
JONATHAN CACHAT ET AL: "Unique and potent effects of acute ibogaine on zebrafish: The developing utility of novel aquatic models for hallucinogenic drug research", BEHAVIOURAL BRAIN RESEARCH., vol. 236, 1 January 2013 (2013-01-01), NL, pages 258 - 269, XP055407280, ISSN: 0166-4328, DOI: 10.1016/j.bbr.2012.08.041 *
KENNETH R. ALPER ET AL: "Treatment of Acute Opioid Withdrawal with Ibogaine", AMERICAN JOURNAL OF ADDICTIONS, vol. 8, no. 3, 1 January 1999 (1999-01-01), US, pages 234 - 242, XP055223410, ISSN: 1055-0496, DOI: 10.1080/105504999305848 *
KOENIG XAVER ET AL: "Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: A study to assess the drug's cardiac ion channel profile", TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. 273, no. 2, 22 May 2013 (2013-05-22), pages 259 - 268, XP028784922, ISSN: 0041-008X, DOI: 10.1016/J.TAAP.2013.05.012 *

Also Published As

Publication number Publication date
AU2015225442A1 (en) 2016-10-20
EP3113771A1 (en) 2017-01-11
CA2978537A1 (en) 2015-09-11
WO2015134405A1 (en) 2015-09-11
CA2978537C (en) 2023-10-24
AU2020273281A1 (en) 2020-12-17
CA3212001A1 (en) 2015-09-11

Similar Documents

Publication Publication Date Title
EP3429635A4 (en) Anti-crispr compounds and methods of use
EP3504213A4 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
HK1243073A1 (en) Therapeutic compounds and uses thereof
EP3548033A4 (en) Compounds and their methods of use
EP3377070A4 (en) Compounds and methods of their use
EP3359168A4 (en) Therapeutic compounds and methods
EP3245291A4 (en) Novel micro-dystrophins and related methods of use
GB201403093D0 (en) Therapeutic compounds and their use
EP3373969A4 (en) Glycan-interacting compounds and methods of use
EP3102200A4 (en) Therapeutic compounds and compositions
EP3218005A4 (en) Glycan-interacting compounds and methods of use
EP3116511A4 (en) Compositions of selenoorganic compounds and methods of use thereof
EP3116898A4 (en) Use of aav-expressed m013 protein as an anti-inflammatory therapeutic
EP3134088A4 (en) Bicylcic pyrazolone compounds and methods of use
EP3526205A4 (en) Therapeutic compounds and methods of use thereof
EP3113771A4 (en) Therapeutic uses of ibogaine and related compounds
EP3188721A4 (en) Human therapeutic agents
EP3541847A4 (en) Glycan-interacting compounds and methods of use
EP3117827A4 (en) Composition for vagina and use of the composition
EP3231793A4 (en) Dihydropyrimidine-2-one compounds and medicinal uses thereof
EP3297619A4 (en) Therapeutic uses of l-4-chlorokynurenine
EP3384921A4 (en) New use of thiopeptin
EP3350196A4 (en) Carborane compounds and methods of use thereof
EP3107546A4 (en) Therapeutic methods employing noribogaine and related compounds
EP3442618A4 (en) Loading of disposable

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20161003

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170926

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/32 20060101ALI20170920BHEP

Ipc: A61K 31/404 20060101ALI20170920BHEP

Ipc: A61P 25/34 20060101ALI20170920BHEP

Ipc: A61P 25/36 20060101ALI20170920BHEP

Ipc: A61K 31/55 20060101AFI20170920BHEP

Ipc: A61P 25/30 20060101ALI20170920BHEP

Ipc: A61K 31/4738 20060101ALI20170920BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180424